AbCellera Q2 revenue drops 78% to $10M; net loss widens to $0.11/share

AbCellera Biologics Inc.

2023-Q2 EPS reported -$0.24 revenue$22,248,000

Total revenue $10.1M vs $45.9M in Q2 2022; research fees fell to $9.8M from $12.5M.
Net loss $30.5M ($0.11/sh) vs net loss $6.8M ($0.02/sh) in Q2 2022; R&D spending rose to $36.5M.
Cash, equivalents and marketable securities $822.9M; secured $220M in strategic financing from Canadian govts.
Cumulative partnered program starts up 20% YoY to 106; 9 molecules advanced to clinic vs 6 a year ago.
Total programs under contract 177 with 41 partners, up from 164 and 38 a year ago.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

AbCellera Biologics Inc. reported the second quarter of 2023 results: revenue $10.1 million, net income $30.5 million, EPS $(0.11) per share on a basic and diluted basis.

Period: the second quarter of 2023
Revenue: $10.1 million
Net income: $30.5 million
EPS: $(0.11) per share on a basic and diluted basis
Result: reported results

Exact text from the filing

this funding will drive value in multiple dimensions of our business, including advancing more pre-partnered programs to the clinic.” Q2 2023 Business Summary ● Earned $10.1 million in total revenue. ● Generated a net loss of $30.5 million, compared to a net loss of $6.8 million in Q2 2022. ● Maintained a cumulative total of 177 programs under contract with

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AbCellera Biologics Inc. reported financial results for quarter ended June 30, 2023.

Period: quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 3, 2023, AbCellera Biologics Inc., (the “Company”), issued a press release announcing its financial and operational results for the quarter ended June 30, 2023.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

AbCellera Biologics Inc. filing history →

Source: SEC EDGAR

accession 0001703057-23-000020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.